

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA - Bimekizumab for treating moderate to severe
hidradenitis suppurativa**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

The disease is more common in women than in men. People of African-Caribbean family background have a higher incidence than people of European family background.

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

Issues related to differences in prevalence or incidence of a disease cannot typically be addressed in a technology appraisal. However the appraisal committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population.
--

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
N/A

Approved by Associate Director (name): ...Janet Robertson.....

Date: 06/02/2024